Kiniksa Pharmaceuticals (KNSA) News Today $20.21 -0.32 (-1.56%) Closing price 04:00 PM EasternExtended Trading$20.21 0.00 (0.00%) As of 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari Sells 12,000 SharesApril 17 at 5:31 AM | insidertrades.comEvercore ISI Sticks to Their Buy Rating for Kiniksa Pharmaceuticals (KNSA)April 16 at 11:20 PM | markets.businessinsider.comWedbush Keeps Their Buy Rating on Kiniksa Pharmaceuticals (KNSA)April 16 at 11:20 PM | markets.businessinsider.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Up 6.3% - Still a Buy?Kiniksa Pharmaceuticals (NASDAQ:KNSA) Stock Price Up 6.3% - What's Next?April 16 at 4:39 PM | marketbeat.comJPMorgan Chase & Co. Acquires 277,827 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)JPMorgan Chase & Co. boosted its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 138.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 477,800 shares of the company's stock after purchasingApril 16 at 3:20 AM | marketbeat.comKiniksa Pharmaceuticals (KNSA) Expected to Announce Earnings on TuesdayKiniksa Pharmaceuticals (NASDAQ:KNSA) will be releasing earnings before the market opens on Tuesday, April 22, Financial Modeling Prep reports.April 16 at 2:30 AM | marketbeat.comWellington Management Group LLP Has $1.38 Million Stock Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Wellington Management Group LLP grew its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 46.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 69,813 shares of the company's stock after purchasing an adApril 15 at 3:30 AM | marketbeat.comArrowstreet Capital Limited Partnership Reduces Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Arrowstreet Capital Limited Partnership cut its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 86.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,453 shares of the company'sApril 15 at 3:22 AM | marketbeat.comVanguard Group Inc. Has $63.44 Million Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Vanguard Group Inc. cut its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 2.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,207,497 shares of the company'sApril 14 at 3:22 AM | marketbeat.comTrexquant Investment LP Has $1.60 Million Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Trexquant Investment LP lowered its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 47.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 80,842 shares of the company's stock after selling 74,350April 12, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Kiniksa Pharmaceuticals (KNSA) and Tourmaline Bio (TRML)April 11, 2025 | markets.businessinsider.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives $37.17 Average Target Price from BrokeragesApril 10, 2025 | americanbankingnews.comADAR1 Capital Management LLC Sells 270,262 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)ADAR1 Capital Management LLC lowered its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 61.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 166,406 shares of the company's stock after selling 270,262 shares during tApril 9, 2025 | marketbeat.comExodusPoint Capital Management LP Grows Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)ExodusPoint Capital Management LP lifted its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 965.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 127,161 shares of the companApril 9, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives Consensus Recommendation of "Buy" from BrokeragesKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) has received a consensus rating of "Buy" from the six ratings firms that are presently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average 12-month target price among brokersApril 8, 2025 | marketbeat.comPrudential Financial Inc. Has $1.82 Million Stock Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Prudential Financial Inc. lowered its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 22.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 91,920 shares of the company's stoApril 6, 2025 | marketbeat.comPictet Asset Management Holding SA Decreases Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Pictet Asset Management Holding SA lessened its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 6.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,133,931 shares of the company's sApril 2, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Purchases 32,393 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Charles Schwab Investment Management Inc. boosted its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 36.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 122,019 sharMarch 30, 2025 | marketbeat.comRaymond James Financial Inc. Takes Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Raymond James Financial Inc. acquired a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 199,953 sMarch 27, 2025 | marketbeat.comAdvantage Alpha Capital Partners LP Lowers Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Advantage Alpha Capital Partners LP lessened its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 56.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 8,890 shares of the cMarch 25, 2025 | marketbeat.comKnights of Columbus Asset Advisors LLC Sells 11,790 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Knights of Columbus Asset Advisors LLC lessened its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 16.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 60,966 shares of the company's stMarch 24, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Bought by Bank of New York Mellon CorpBank of New York Mellon Corp increased its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 33.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 122,051 shares of the company's stock afterMarch 22, 2025 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Trading Up 4.4% - Time to Buy?Kiniksa Pharmaceuticals (NASDAQ:KNSA) Trading 4.4% Higher - Still a Buy?March 21, 2025 | marketbeat.comInsider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Sells 8,879 Shares of StockKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) CFO Mark Ragosa sold 8,879 shares of the company's stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $23.10, for a total value of $205,104.90. Following the completion of the sale, the chief financial officer now directly owns 23,382 shares in the company, valued at $540,124.20. This trade represents a 27.52 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.March 20, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Mark Ragosa Sells 11,464 SharesKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) CFO Mark Ragosa sold 11,464 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $23.10, for a total transaction of $264,818.40. Following the transaction, the chief financial officer now owns 23,382 shares in the company, valued at $540,124.20. The trade was a 32.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.March 20, 2025 | marketbeat.comMark Ragosa Sells 8,879 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockMarch 20, 2025 | insidertrades.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Acquired by Globeflex Capital L PGlobeflex Capital L P grew its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 217.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 88,596 shares of the company's stock after purchasingMarch 16, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Sells 17,118 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Connor Clark & Lunn Investment Management Ltd. reduced its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 5.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 306,946 shares of the company's stock after selling 17March 16, 2025 | marketbeat.comMichael R. Megna Sells 9,051 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) CAO Michael R. Megna sold 9,051 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total value of $203,194.95. Following the transaction, the chief accounting officer now owns 26,528 shares of the company's stock, valued at approximately $595,553.60. This trade represents a 25.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.March 15, 2025 | marketbeat.comMark Ragosa Sells 36,372 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) CFO Mark Ragosa sold 36,372 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $22.25, for a total transaction of $809,277.00. Following the completion of the sale, the chief financial officer now directly owns 22,958 shares in the company, valued at $510,815.50. This represents a 61.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.March 15, 2025 | marketbeat.comInsider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Sells 9,051 Shares of StockMarch 15, 2025 | insidertrades.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives Consensus Recommendation of "Buy" from AnalystsShares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) have been given an average recommendation of "Buy" by the five research firms that are currently covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a buy rating. The average 1-yearMarch 14, 2025 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Earns Buy Rating from Analysts at CitigroupCitigroup began coverage on Kiniksa Pharmaceuticals in a research note on Thursday. They set a "buy" rating and a $40.00 target price for the company.March 14, 2025 | marketbeat.com3 No-Brainer Healthcare Stocks to Buy With $1,000 Right NowMarch 14, 2025 | fool.comCitigroup Initiates Coverage of Kiniksa Pharmaceuticals (KNSA) with Buy RecommendationMarch 14, 2025 | msn.comKiniksa initiated with a Buy at CitiMarch 13, 2025 | markets.businessinsider.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Essex Investment Management Co. LLCEssex Investment Management Co. LLC lowered its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 13.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 173,799 shares of the coMarch 10, 2025 | marketbeat.comPrincipal Financial Group Inc. Sells 25,944 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Principal Financial Group Inc. trimmed its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 49.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 26,907 shares of the company's stock aftMarch 7, 2025 | marketbeat.comKiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan AnalystMarch 6, 2025 | benzinga.comIs Kiniksa Pharmaceuticals International, plc (KNSA) the Best UK Growth Stock to Buy Now?March 6, 2025 | msn.comY Intercept Hong Kong Ltd Invests $258,000 in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Y Intercept Hong Kong Ltd bought a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 13,050 shares of the company's stock,March 5, 2025 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Trading Up 9.3% - Here's WhyKiniksa Pharmaceuticals (NASDAQ:KNSA) Trading 9.3% Higher - Still a Buy?March 3, 2025 | marketbeat.comShort Interest in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Grows By 53.4%Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) was the target of a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 2,960,000 shares, an increase of 53.4% from the January 31st total of 1,930,000 shares. Based on an average daily trading volume, of 463,600 shares, the short-interest ratio is currently 6.4 days.March 3, 2025 | marketbeat.comIs Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stocks to Buy Now?March 2, 2025 | msn.comLos Angeles Capital Management LLC Has $1.10 Million Stock Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Los Angeles Capital Management LLC lowered its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 44.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 55,528 shares of the company's stock after selliMarch 2, 2025 | marketbeat.comEvercore ISI Remains a Buy on Kiniksa Pharmaceuticals (KNSA)February 28, 2025 | markets.businessinsider.comWedbush Equities Analysts Raise Earnings Estimates for KNSAKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Wedbush boosted their Q1 2025 earnings per share estimates for Kiniksa Pharmaceuticals in a report issued on Tuesday, February 25th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of $0.31 per share for tFebruary 27, 2025 | marketbeat.comKiniksa price target lowered to $30 from $35 at Wells FargoFebruary 26, 2025 | markets.businessinsider.comKiniksa issues updates on abiprubart, KPL-387, mavrilimumabFebruary 26, 2025 | msn.comBig Pipeline Updates From Kiniksa PharmaceuticalsFebruary 25, 2025 | seekingalpha.com Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address KNSA Media Mentions By Week KNSA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KNSA News Sentiment▼0.840.80▲Average Medical News Sentiment KNSA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KNSA Articles This Week▼134▲KNSA Articles Average Week Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Legend Biotech News Telix Pharmaceuticals Limited American Depositary Shares News Sarepta Therapeutics News Blueprint Medicines News Axsome Therapeutics News Nuvalent News ADMA Biologics News Krystal Biotech News Grifols News Cytokinetics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KNSA) was last updated on 4/17/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
